ArticleFrontiers in oncology2020
Next-Generation Sequencing of
Open access · goldAbstract read
In one paragraph
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis.Annals of hematology · 2025Pooled it
- Germline DDX41 mutations in myeloid neoplasms: a comprehensive review.The Korean journal of internal medicine · 2026Review
- Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.British journal of haematology · 2026Article
- Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.Leukemia · 2026Article
- Moving Beyond Somatic Alterations: Uncovering the Germline Basis of Myeloid Malignancies.Cancers · 2026Review
- Single vs dual genetic disease in children with congenital anomalies and solid tumors.Genetics in medicine open · 2026Article
- Genomic variation in DDX41 identified through clinical sequencing.British journal of haematology · 2025Article
- Germline Cancer Susceptibility Variants in Patients With Uveal Melanoma.Pigment cell & melanoma research · 2025Article
- Overall cancer risk in people with deleterious germlineHaematologica · 2025Article
- Detecting likely germline variants during tumor-based molecular profiling.The Journal of clinical investigation · 2025Review
- Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding.Current opinion in hematology · 2025Review
- Myelodysplastic syndrome with dual germline RUNX1 and DDX41 variants: a rare genetic predisposition case.Familial cancer · 2025Article
- Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.European urology open science · 2025Article
- How to manage patients with germlineHemaSphere · 2024Article
- Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia.JCO precision oncology · 2024Article
- Evaluation of the pathogenic potential of germline DDX41 variants in hematopoietic neoplasms using the ACMG/AMP guidelines.International journal of hematology · 2024Review
- Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.Transplantation and cellular therapy · 2024Review
- DDX41: exploring the roles of a versatile helicase.Biochemical Society transactions · 2024Review
- Multifunctional role of DEAD-box helicase 41 in innate immunity, hematopoiesis and disease.Frontiers in immunology · 2024Review
- Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With a GermlineCase reports in hematology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 1 institution in 1 country.
Sarah A BannonDepartment of Clinical Cancer Genetics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Mark J RoutbortDepartment of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Guillermo Montalban-BravoDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Rohtesh S MehtaDepartment of Stem Cell Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Fatima Zahra JelloulDepartment of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Koichi TakahashiDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Naval DaverDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Betul OranDepartment of Stem Cell Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Naveen PemmarajuDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Gautam BorthakurDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Kiran NaqviDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Ghayas IssaDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Koji SasakiDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Yesid AlvaradoDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Tapan M KadiaDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Marina KonoplevaDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Rashmi Kanagal ShamannaDepartment of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Joseph D KhouryDepartment of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Farhad RavandiDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Richard ChamplinDepartment of Stem Cell Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Hagop M KantarjianDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Kapil BhallaDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Keyur P PatelDepartment of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
Courtney D DiNardoDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
The University of Texas MD Anderson Cancer Center · US
Funding
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1R01CA255721 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHALLA, KAPIL, DINARDO, COURTNEY · 2021 to 2025
$2.4MNCI NIH HHS R01 CA255721
Abstract
Previously considered rare, inherited hematologic malignancies are increasingly identified. Germline mutations in the RNA helicase
Indexed as
AMLDDX41germlinehereditaryMDS
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.